Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ​​NRG-HN002: chemoradiotherapy for p16-positive low-risk HPV-associated oropharyngeal carcinoma

Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the randomised Phase II NRG-HN002 trial (NCT02254278), which investigated chemoradiotherapy for patients with p16-positive low-risk HPV-associated oropharyngeal carcinoma. Patients were randomised to receive either 60 Gy intensity-modulated radiation therapy with concurrent cisplatin (IMRT-C) or 60 Gy accelerated IMRT. The primary endpoints were progression-free survival (PFS) of 85% at 2-years and acceptable swallowing toxicities. Both arms of the trial achieved acceptable swallowing outcomes and the chemoradiotherapy arm achieved a significantly higher PFS, which has led to this treatment regimen being taken forward into further trials (NRG-HN005, NCT03952585). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.